Advertisement
Abstract| Volume 45, SUPPLEMENT 2, S163, November 2022

Predictive factors of response to Cabazitaxel in heavily pretreated patients with metastatic castration resistant prostate cancer: RWD from eight Portuguese institutions

Open AccessDOI:https://doi.org/10.1016/S2666-1683(22)02530-7
Predictive factors of response to Cabazitaxel in heavily pretreated patients with metastatic castration resistant prostate cancer: RWD from eight Portuguese institutions
Previous ArticleRash in patients treated with apalutamide in different prostate cancer settings. A real world study
Next ArticleAssociation between prostate-specific antigen decline and survival outcomes in patients with metastatic castrate-resistant prostate cancer treated with first line abiraterone acetate
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S2666-1683(22)02530-7

      Copyright

      © 2022 European Association of Urology. Published by Elsevier B.V. Published by Elsevier Inc.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX